Sarepta Therapeutics (SRPT) FY2021 results: revenue $702 million, up 30.0% on the year
Sarepta Therapeutics, Inc. (SRPT) reported revenue of $702 million for fiscal 2021, the year ended 31 December 2021, up 30.0% on the year before. Net income was -$419 million, and diluted earnings per share $-5.15. The figures are the company's own, from the 10-K it filed with the SEC on 1 March 2022.
Revenue
$702 million
+30.0% on the year
FY2014FY2021
Operating margin
-65.5%
-104.5% a year earlier
FY2014FY2021
Net income
-$419 million
FY2014FY2021
Diluted EPS
-$5.15
FY2014FY2021
this yearthe year beforeHover a bar for its figure.
$ million except per share. Read moreFree cash flow is operating cash flow less capital expenditure; the effective tax rate is income tax over pre-tax income; margins are the line over revenue. Gross profit is revenue less cost of revenue, and operating income is revenue less the company's own total costs, where the statement does not print those lines. Those four are arithmetic on the filed numbers; everything else is as filed. Money is in $ million as the company files it, or in $ billion by the switch above the tables; per share figures and share counts are as they are.
Cash flow
$ million
FY2021
FY2020
FY2019
On the year
Last 8 years
Operating cash flow
-443
107
-456
Capital expenditure
38.5
82.2
59.6
-53.2%
Free cash flow
-482
25.3
-516
Free cash flow margin
-68.6%
4.7%
-135.5%
Cash from investing
495
-122
287
Cash from financing
562
682
643
-17.7%
Depreciation and amortisation
38.0
26.9
24.5
+41.3%
Share-based compensation
114
108
78.6
+5.4%
Diluted shares, weighted
81m
78m
74m
+4.2%
Shares outstanding at period end
87m
79m
75m
+9.8%
Balance sheet
$ million
FY2021
FY2020
FY2019
On the year
Last 8 years
Shareholders' equity
928
762
818
+21.8%
Debt
1,097
992
682
+10.5%
Operating lease liabilities
41.5
80.4
47.7
-48.3%
Other liabilities
1,082
1,150
275
-6.0%
Total liabilities and equity
3,148
2,985
1,823
+5.5%
Fixed assets
191
190
130
+0.4%
Intangible assets
14.2
13.6
12.5
+4.5%
Investments
0.0
436
290
Cash and equivalents
2,116
1,503
835
+40.8%
Receivables
153
101
90.9
+51.0%
Inventory
186
232
171
-19.7%
Other assets
488
509
294
-4.2%
Total assets
3,148
2,985
1,823
+5.5%
10-K for the year ended 31 December 2021, filed 1 March 2022: the filing.